The Women’s Alcohol and Drug Service (WADS) has noted an increase in infants exposed to methamphetamines and GHB in utero, reflecting rising substance use among individuals of childbearing age in the community. However, limited research on the effects of these drugs during pregnancy has resulted in scarce evidence-based treatment options for affected mothers and infants. To address this gap, WADS has implemented a First Thousand Days Clinic aimed at mitigating risks associated with drug exposure, promoting maternal-infant attachment, and ensuring optimal growth and development of affected infants. This presentation will outline early findings from the clinic and discuss how they will contribute to establishing guidelines and best practices for early intervention and integrated care, addressing the complex needs of families impacted by substance use.
Responding to changing drug use patterns in pregnancy
Kerri Felemonow | Manager of The Women’s Alcohol and Drug Service, The Women’s Hospital
Kerri Felemonow is the Manager of The Women’s Alcohol and Drug Service (WADS) . Kerri has completed Bachelor Degrees in Legal Studies and Social Work, a Grad Cert in AOD and a Master in Advanced Social Work. She is passionate about working to improve health outcomes for women and infants affected by alcohol and other drugs.
Violetta Solarte | Social Worker, The Women’s
Violeta is a social worker at the First Thousand Days clinic, supporting women and babies during the crucial early years of life. Violeta is qualified with a Masters of Social Work from the University of Melbourne, she helps vulnerable families access vital health and psychosocial support.
Credited Persons
Anna Tottman | Neonatologist, The Women’s Hospital